About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT03517059

Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease

Pilot study: * Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD) * Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on and off drug condi...

Lead sponsor: University Hospital, Lille•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Lille

Collaborators

France Parkinson Association

Prospective, clinical assessment of : * Cognition and diadochokinetic task during fMRI in 30 PD patients (in off and on condition) * Motor assessment using VICON gait and balance analysis * Pulmonary functional testing in OFF and ON drug condition * Quality of life * Clinical neurological MDS UPDRS , N Fog questionnaire * ENT and speech therapist evaluation in OFF and ON drug condition

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Parkinson's Disease group :
•Patients with Parkinson's Disease, who where included in the PRODYGI-1 cohort still meeting the MP criteria, Always followed in the service of neurology and pathology of the movement.
•Pathological control group:
•Patients suffering from Richardson syndrome.
•Aged over 18
•Healthy control group:
•Age-matched (± 5 years)
•Recruited on the basis of volunteering.
•free from any progressive neurological pathology after clinical examination and MoCA.

Exclusion Criteria

•For all groups:
•Pregnant or lactating woman
•Extra-neurological severe respiratory pathology
•Terminal heart failure
•Contraindication to MRI
•Refusal / withdrawal / inability to give consent
•ENT pathology.

Related studies

Apathy in Parkinson Disease TMS Study

NCT06087926 · Parkinson Disease

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

NCT07642908 · Parkinson Disease

RECRUITINGPhase 2

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830 · Parkinson Disease, Parkinson, and more

Cognitive Decline Following Deep Brain Stimulation

NCT05822388 · Parkinson Disease, Movement Disorders

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

NCT06965374 · Parkinson Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 23, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment29

Start dateMay 2017

Last updatedDec 23, 2025

Condition

Parkinson Disease

Locations shown

Hôpital Roger Salengro, CHRU

Lille

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 23, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions